AIM
GYRE icon

Alambic Investment Management’s Gyre Therapeutics GYRE Stock Holding History

Alambic Investment Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,357
Closed -$76K – 23
2020
Q3 		$76K Buy
+2,357
New +$92.2K 0.83% 43

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alambic Investment Management's GYRE Position: Q4 2020 in Review

Alambic Investment Management sold out of Gyre Therapeutics (GYRE) in Q4 2020, closing a stake of 2,357 shares — an estimated $76K sold.

Alambic Investment Management first reported a position in GYRE in Q3 2020 and held it in 1 quarter. The position peaked at $76K in Q3 2020. 80 funds tracked by Wall St. Rank hold GYRE as of Q4 2020.

  • Alambic Investment Management reported no remaining Gyre Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 2,357 Gyre Therapeutics shares in Q4 2020, an estimated $76K.
  • Alambic Investment Management first reported a position in Gyre Therapeutics in Q3 2020 and held it in 1 quarter.
  • Alambic Investment Management's Gyre Therapeutics position peaked at $76K in Q3 2020.
  • 80 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.